Papulopustular Rosacea
Conditions
Brief summary
The overall objective of this study is to assess how the use of the drug may shift the skin microbiome and skin biophysical properties. Specifically, the study objectives were to assess the following: * How the drug affects the skin microbiome compared with vehicle when applied once daily for 8 weeks in subjects with papulopustular rosacea. * How the drug affects the skin physical properties compared with vehicle when applied once daily for 8 weeks in subjects with papulopustular rosacea.
Interventions
DRUGEncapsulated Benzoyl Peroxide Cream
Subjects will use a pea-size amount for each area of the face
Sponsors
Sol-Gel Technologies, Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants must sign an Institutional Review Board (IRB) approved written informed consent for this study. * Male and female 18 years of age and older. * Participants must have clinical diagnosis of moderate to severe rosacea. * Have a minimum total of 15 and a maximum of 70 total inflammatory lesions (papules and/or pustules) including those present on the nose. * Have 2 nodules or less.
Exclusion criteria
* Females, who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation or were found to have positive pregnancy test at Baseline or screening visits. * Presence of more than 2 facial nodules or any nodule greater than 1 centimeter (cm). * Current or past ocular rosacea (for example, conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in colorimeter test after 8-weeks of treatment compared to baseline. | 8-weeks | facial L\*a\*b\* values |
| Change in skin microbiome diversity after 8-weeks of treatment compared to baseline | 8-weeks | Facial microbiome sampling will be performed on-site by collecting follicular samples as well as utilizing facial swabs. |
| Change in transepidermal water loss after 8-weeks of treatment compared to baseline. | 8-weeks | transepidermal water loss in g/m2/h |
| Change in stratum corneum hydration after 8-weeks of treatment compared to baseline. | 8-weeks | stratum corneum water content (wt%) |
| Change in sebum excretion rate after 8-weeks of treatment compared to baseline. | 8-weeks | sebum production in µg/cm2 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in skin microbiome diversity after 30 minutes, 1-week, 2-weeks and 4-weeks of treatment compared to baseline | 4-weeks | Facial microbiome sampling will be performed on-site by collecting follicular samples as well as utilizing facial swabs. |
| Change in transepidermal water loss after 1-week, 2-weeks and 4-weeks of treatment compared to baseline. | 4-weeks | transepidermal water loss in g/m2/h |
| Change in stratum corneum hydration after 1-week, 2-weeks and 4-weeks of treatment compared to baseline. | 4-weeks | stratum corneum water content (wt%) |
| Change in sebum excretion rate after 1-week, 2-weeks and 4-weeks of treatment compared to baseline. | 4-weeks | sebum production in µg/cm2 |
| Change in colorimeter test after 1-week, 2-weeks and 4-weeks of treatment compared to baseline. | 4-weeks | facial L\*a\*b\* values |
Countries
United States
Outcome results
None listed